Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss  by Fidler, Samantha et al.
Transplant Immunology 29 (2013) 22–27
Contents lists available at ScienceDirect
Transplant Immunology
j ourna l homepage: www.e lsev ie r .com/ locate / t r imPeri-operative third party red blood cell transfusion in renal
transplantation and the risk of antibody-mediated rejection
and graft loss
Samantha Fidler a,b,1, Ramyasuda Swaminathan c,d,2, Wai Lim e,3, Paolo Ferrari f,4, Campbell Witt a,b,5,
Frank T. Christiansen a,b,6, Lloyd J. D'Orsogna a,b,7, Ashley B. Irish c,d,⁎,8
a Department of Clinical Immunology, PathWest, Royal Perth Hospital, Western Australia, Australia
b School of Pathology and Laboratory Medicine, University of Western Australia, Australia
c Medical Renal Transplant Unit, Royal Perth Hospital, Western Australia, Australia
d School of Medicine and Pharmacology, University of Western Australia, Australia
e Department of Nephrology Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
f Department of Nephrology Fremantle Hospital, Fremantle, Western Australia, AustraliaAbbreviations: AMR, antibody-mediated rejection; RB
cPRA, calculated panel reactive antibody; DSA, donor sp
graft function; BPAR, biopsy proven acute rejection; MF
SAB, single antigen bead.
⁎ Corresponding author at: Medical Renal Transplant U
Box X2213, Perth, Western Australia 6847, Australia. Tel.:
9224 2160.
E-mail address: Ashley.Irish@health.wa.gov.au (A.B. Ir
1 Participated in the performance of research laborator
writing the paper.
2 Participated with data collection and analysis.
3 Participated with data collection and writing the pape
4 Participated with data collection and writing the pape
5 Participated in research design, data analysis and wri
6 Participated in research design and writing the paper
7 Participated in data analysis and writing the paper.
8 Participated in research design, data collection and an
0966-3274 Crown Copyright © 2013 Published by Elsevie
http://dx.doi.org/10.1016/j.trim.2013.09.008a b s t r a c ta r t i c l e i n f oArticle history:
Received 12 August 2013
Received in revised form 23 September 2013
Accepted 23 September 2013
Keywords:
Donor-speciﬁc antibody (DSA)
Peri-operative transfusion
Kidney transplantation
Antibody mediated rejectionHistoric red blood cell transfusion (RBCT)may induce anti-HLA antibodywhich, if donor speciﬁc (DSA), is associated
with increased antibody-mediated rejection (AMR).Whether post-operative RBCT inﬂuences this risk is unknown.
We examined the RBCT history in 258 renal transplant recipients stratiﬁed according to prevalent recipient HLA
antibody (DSA, Non-DSA or No Antibody).
AMR occurred more frequently in patients who received RBCT both pre and post transplant compared with all
other groups (Pre + Post-RBCT 21%, Pre-RBCT 4%, Post-RBCT 6%, No-RBCT 6%, HR 4.1 p = 0.004). In the 63 pa-
tients who received Pre + Post-RBCT, 65% (13/20)with DSA developed AMR comparedwith 0/6 in the Non-DSA
group and 2/37 (5%) in the No-Antibody group (HR 13.9 p b 0.001). In patientswho receivedNo-RBCT, Pre-RBCT
or Post-RBCT there was no difference in AMR between patients with DSA, Non-DSA or No-Antibody. Graft loss
was independently associated with Pre + Post-RBCT (HR 6.5, p = 0.001) AMR (HR 23.9 p b 0.001) and Non-
AMR (6.0 p = 0.003) after adjusting for DSA and delayed graft function.
Re-exposure to RBCT at the time of transplant is associated with increased AMR only in patients with preformed
DSA, suggesting that RBCT provides additional allostimulation. Patients receiving Pre + Post-RBCT also had an
increased risk of graft loss independently of AMR or DSA. Both pre and post procedural RBCT in renal transplan-
tation is associated with modiﬁcation of immunological risk and warrants additional study.
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The presence of pre-transplant anti-HLA antibody directed against
the donor antigens (DSA) in the presence of a negative CDC crossmatch
is associated with increased risk of antibody mediated rejection (AMR)
and graft failure [1–3]. HLA antibodies are formed as a consequence of
prior transplantation, pregnancy and blood transfusion due to exposure
to foreign HLA antigens [4–9]. However blood transfusion prior to
transplant is immunomodulatory and appears to reduce the risk of
acute allograft rejection and graft loss despite an increased risk of sensi-
tisation [10–12]. Historically it had been observed that large volumes of
third-party red blood cell transfusion (RBCT) (up to 20 units) over a
prolonged period are required to induce enduring antibodies, especially
in males or nulliparous females [4,13–15]. However in the presence of
another immune stimulating process such as pregnancy or transplanta-
tion, co-administration of third party RBCT results in broad HLA anti-
body production which is more potent and enduring [6,16,17]. In the license.
23S. Fidler et al. / Transplant Immunology 29 (2013) 22–27current transplant era, transfusion in patientswith end stage kidney dis-
ease is less frequent due to the widespread use of epoetins. However
during acute illness or surgery patients may still be exposed to blood
products, although speciﬁcally transfusing patients for immunological
beneﬁt is no longer routine [18–20]. Leucodepletion of blood products
has also been shown not to prevent the risk of allosensitisation associat-
ed with RBCT [14,21–23]. The majority of studies on the role of blood
transfusion was performed in the period before the use of sensitive
and speciﬁc solid phase antibody detection assays were available and
cell-dependent cytotoxicity assays were utilised. Although it is
established that DSA detected at the time of transplant is associated
with an increased risk of AMR why some patients with DSA develop
AMR and others do not is unclear andmay relate to variability in the an-
tibody sub-type, complement binding ability, or the amount or breadth
of antibody [1,24–26]. Transfusion in the peri-operative and early post-
transplant period depends on individualised patient management
factors and is commonly thought not to be an immunological stimulus
because it is assumed that the concomitant use of immunosuppression
mitigates this risk. We hypothesised that post-transplant transfusion
in patients with preformed HLA antibody may provide additional
allostimulation or immunological recall and increase the risk of AMR.
We therefore investigated the relationship of pre-transplant and peri-
operative transfusion in renal transplant recipients with and without
pre-transplant HLA antibody determined by Luminex single antigen
bead (SAB) assay.
2. Subject and methods
2.1. Patients
We studied 258 transplant recipients of which 246 patients received
a kidney transplant and 12 patients received a simultaneous pancreas–
kidney transplant between June 2003 and October 2007. Patients were
transplanted at 3 tertiary centres and peri-operative care and decision
for transfusionswas individualised, clinically indicated and notmandat-
ed by protocol. No donor-speciﬁc transfusions occurred. Leucocyte de-
pleted packed red cells were used. All patients received a calcineurin
inhibitor (CNI) (tacrolimus or cyclosporine) at the time of transplanta-
tion in combination with mycophenolate mofetil or mycophenolate
sodium and corticosteroids and the Interleukin-2 receptor antibody
basiliximab was commonly used for induction. The need for biopsy,
medication adjustments and transfusion was determined by the
caring clinical teams and was not protocol driven. Transfusion history
was obtained from the West Australian Red Cross Blood Bank, the
Westmead Hospital Transfusion Laboratory, patient medical records
and direct patient interrogation. Patient follow-up was a median of
67 months (IQR 54–77). Patients provided written consent for partici-
pation in this study.
2.2. Laboratory methods
These are reported in detail elsewhere however stored donor DNA
was typed by sequence based typing at HLA-A, -B, -C, -DRB1, DQB1,
DPB1 loci and DRB3, 4, 5 and DQA1 where required [27]. All recipients
were transplanted with a negative T cell CDC crossmatch. B cell cross-
matching was performed for 80% of the patients; however a positive B
cell crossmatch was not considered an absolute contraindication to
transplantation. Sera collected at the time of transplant were screened
retrospectively for anti-HLA class I and/or class II antibodies using
the Luminex Mixed Screen assay (OneLambda Inc.) and those with a
positive screen were characterised for HLA class I and/or class II anti-
bodies speciﬁcity using single antigen beads (LABScreen Single Antigen
beads, OneLambda Inc.). Antibodies were considered to be positive if
the normalised mean ﬂuorescence intensity (MFI) value for a particular
bead was greater than 500. HLA antibodies with an MFI N500 directed
against a donor HLA antigen were considered to be DSA.2.3. Clinical outcome parameters
Transfusion history was recorded as never transfused (No-RBCT),
transfused at any time prior to renal transplant but not after renal
transplant surgery (Pre-RBCT), not transfused prior to transplant but
transfused at the time of, or within 30 days of transplant surgery
(Post-RBCT) and transfused both prior to and within 30 days of the
transplant (Pre + Post-RBCT). Delayed graft function (DGF) was de-
ﬁned as the need for dialysis within the ﬁrst 48 h of transplantation.
Graft loss was deﬁned as the return to dialysis (i.e. death-censored) un-
less otherwise indicated. All rejection episodes were proven by biopsy
(BPAR) and the ﬁrst BPAR was used to construct time to event analysis
andwheremultiple rejections occurred, the highest reported gradewas
recorded. Time to AMR was recorded as a separate event to allow anal-
ysis by rejection type (AMR vs Non-AMR). Treatment of rejectionwas at
the treating clinician's discretion and was not mandated by protocol.
Histological reporting of renal biopsies was undertaken by the local his-
topathologists as part of routine clinical care and was initially made
without information as to the presence or absence of DSA (due to vary-
ing laboratory testing and reporting changes over the period of study).
The biopsy ﬁndings were graded according to the Banff classiﬁcation
2003. AMR was deﬁned as C4d positivity in PTC alone or in conjunction
with transplant glomerulitis and/or peri-tubular capillaritis and/or ar-
teritis, and also in the absence of C4d when transplant glomerulitis
and peri-tubular capillaritis were detected.
2.4. Statistical analysis
Statistical analyses were performed by using SPSSv18 (SPSS Inc.,
Chicago IL, USA). For categorical data Fisher's exact test or Pearson's
chi-square tests were used. Parametric data were compared by
ANOVA or t-test, and for non parametric data Mann–Whitney U test
or Kruskal–Wallis one-way ANOVA was used. Comparisons of within
group differences by z-test were made with Bonferroni adjustment
reported at the p b 0.05 level. Time to event of interest (AMR, graft
and patient survival) was estimated by the method of Kaplan–Meier
and Cox proportional hazard regression analysis with the predictor
satisfying the proportional hazard assumption. Covariates examined
were HLA-antibody at entry, rejection, gender, re-transplantation, and
delayed graft function. Results were expressed as hazard ratios (HR)
with 95% CI.
3. Results
Sixty-ﬁve patients had pre-transplant HLA-antibody: DSA group n = 37 (14%) and
Non-DSA group n = 28 (11%) while the remaining 193 (75%) patients had no HLA anti-
body deﬁned using the MFI cut-off of b500 or with a negative antibody screen. Baseline
clinical and demographic data of these groups is reported in detail elsewhere and
summarised in Table 1. [27]As expected, patients with any HLA antibodyweremore com-
monly female (41/65 vs 53/193 p = 0.003) and more likely to have undergone prior kid-
ney transplant (20/65 vs 7/193 p b 0.001) and to have received Pre-RBCT (39/65 vs
70/193 P = 0.011). There was no difference in haemoglobin between the groups
either at time of transplant (DSA 124 ± 19, Non-DSA 124 ± 18, No-Antibody
124 ± 15 g/L p = 0.99) or at 30 days post transplant (DSA 109 ± 17, Non-DSA
113 ± 13, No-Antibody 114 ± 17 g/L p = 0.19). Patients with pre-transplant DSA
were signiﬁcantly more likely to have been transfused within the ﬁrst 30 peri-operative
days (DSA 70%) than those with Non-DSA (43%) or no HLA antibody (38% p b 0.001)
although the amount of RBCT was not different [DSA 4 (2–4), Non-DSA 2 (2–4) and No-
Antibody 2 (2–4) units median and IQR p = 0.17] and N90% of all post-transplant RBCT
given within the ﬁrst 2 peri-operative days.
In order to explore further the relationship between transfusion and pre-transplant
DSA we divided the patients into four groups according to their transfusion status— No-
RBCT, Pre-RBCT, Post-RBCT and Pre + Post-RBCT groups as previously deﬁned (Table 2).
Overall 109/258 (42%) received Pre-RBCT and 111/258 (43%) of patients received Post-
RBCT. The prevalence of HLA antibody amongst these groups varied signiﬁcantly as
expected. The No-RBCT group were much more likely to have no HLA antibody (86%)
than the other groups (p b 0.05). Conversely however, the Pre + Post-RBCT group were
more likely to have DSA (p b 0.05), receive a repeat transplant and less likely to receive
a pre-emptive or living donor transplant, although time on dialysis was similar to
those with Pre- and Post-RBCT. Patients with Pre-RBCT only were signiﬁcantly less likely
to have Non-AMR rejection than all other groups (p b 0.05 Table 3). Patients in the
Table 3
Univariate and multivariate adjusted Cox Proportional Hazards models for the effect of
Delayed Graft Function (DGF), entry HLA antibody, Antibody and Non-AntibodyMediated
Rejection (AMR and Non-AMR) and Transfusion status on death censored and combined
patient and graft loss.
Death censored graft loss
N = 27
Combined patient and graft loss
N = 51
Univariate Multivariate Univariate Multivariate
DGF 2.1 (0.92–4.8)
0.078
0.9 (0.4–2.1)
0.73
2.5 (1.5–4.5)
0.002
1.5 (0.8–2.8)
0.23
Non-DSA 1.4 (0.47–4.2)
0.54
1.3 (0.4–4)
0.73
1.0 (0.5–2.0)
0.93
0.9 (0.3–2.1)
0.74
DSA 2.6 (1.1–6.4)
0.034
0.56 (0.2–1.6)
0.28
2.2 (1.1–4.2)
0.024
0.93 (0.4–2.0)
0.86
Non-AMR 7.0 (2.3–21.5)
0.001
6.0 (1.9–19.3)
0.003
2.3 (1.2–4.2)
0.012
2.0 (1.0–3.8)
0.048
AMR 25.8 (8–83.2)
b0.001
23.9 (6.9–83.2)
b0.001
6.0 (2.9–12.5)
b0.001
4.8 (2.1–10.8)
b0.001
Pre-RBCT 0.5 (0.1–4.6)
0.55
0.64 (0.1–6.0)
0.70
1.8 (0.7–4.7)
0.22
2.2 (0.8–5.8)
0.12
Post-RBCT 2.7 (0.8–9.7)
0.13
2.6 (0.7–9.6)
0.15
1.6 (0.6–4.2)
0.32
1.6 (0.6–4.1)
0.37
Pre + Post-RBCT 7.1 (2.4–7.3)
b0.001
6.5 (2.0–21.6)
0.002
5.1 (2.9–10.9)
b0.001
3.9 (1.7–8.9)
0.001
Table 1
Demographic and clinical features at time of transplant by entry HLA-antibody.
NoHLA antibody
n = 193
HLA antibody n = 65
Non-DSA
n = 28
DSA
n = 37
P value
Age at transplant (years) 47 ± 13 46 ± 11 44 ± 11 0.45
Recipient female N (%) 53 (28)a 19 (68) 22 (60) b0.001
Cadaveric N (%) 118 (61) 21 (75) 28 (76) 0.11
Repeat transplant N (%) 7 (4)a 9 (32) 11 (30) b0.001
Pre-emptive transplant N (%) 22 (11) 2 (7) 3 (8) 0.70
Months on dialysis 25 (9–51) 38 (12–54) 50 (13–82) 0.042
HLA mismatch 3 (3–4) 2 (1–4) 3 (2–4) 0.11
DGF N (%) 34 (18) 3 (11) 10 (27) 0.22
IL2R-Ab induction N (%) 87 (47) 15 (54) 25 (68) 0.65
Anti-T cell induction N (%) 3 (2) 1 (4) 2 (5)
Initial CNI tacrolimus N (%) 123 (64) 16 (57) 28 (76) 0.26
Pre-RBCT N (%) 70 (36)a 16 (57) 23 (62) 0.003
Units of RBCT 5 (2–9) 5 (2–9) 5 (4–13) 0.69
Post-RBCT N (%) 73 (38) 12 (43) 26 (70)# 0.001
Units of RBCT 2 (2–4) 2 (2–4) 4 (2–4) 0.17
Haemoglobin at transplant g/L 124 ± 15 124 ± 18 124 ± 19 0.99
Haemoglobin at 1 month g/L 114 ± 17 113 ± 13 109 ± 17 0.19
a Signiﬁcantly different from Non-DSA and DSA at the p b 0.05 level.
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4 fold increased risk of AMR (Table 3 and Fig. 1 p = 0.004) with a median time to AMR
of 2 months.
Given the association of Pre + Post RBCT with AMR we next examined the impor-
tance of pre-transplant DSA, a known risk for AMR, in the various transfusion groups.
When stratiﬁedby thepresenceof DSA therewasnodifference in the risk of AMRbetween
those with or without DSA in either of the No-RBCT, Pre-RBCT or Post-RBCT groups indi-
vidually (data not shown) or when these 3 groups were combined (Fig. 2a). In the
Pre + Post RBCT group the risk of AMR was 13.9 times greater in those patients with
DSA than in patients with Non-DSA or No-Antibody (Fig. 2b p = 0.001). Indeed all 13
episodes of AMR in the DSA group occurred exclusively in patients who had received
Pre + Post-RBCT. On the other hand, 0/6 patients with Non-DSA and 2/37 in the No-
antibody group who had received Pre + Post-RBCT developed AMR. The median time
between post-operative transfusion and AMR in the DSA patients was 25 days (IQR
5–761 days).
Univariate predictors of AMR were pre-transplant DSA (HR 6.6 95%CI 2.9–14.7,
p b 0.001), DGF (HR 2.6. 1.1–6.1, p = 0.039), re-transplant (HR 3.3 1.3–8.3 p = 0.024)
and Pre + Post-RBCT (HR 4.1, 1.6–10.8 p = 0.005) but not females (HR 0.9 0.38–2.1).
There was a signiﬁcant interaction between Pre-RBCT and Post-RBCT (HR 4.4 2.0–9.8
p = 0.001) and between DSA and Post-RBCT (HR 10.6 4.7–23.8 p b 0.0001) on the risk
of AMR. In amultivariate Coxmodel incorporating the above univariate factors and addingTable 2
Patient demographics, HLA antibody, rejection and outcomes by transfusion status.
No-RBCT
N = 101
Pre-RBCT
N = 46
Age at transplant (years) 43 ± 13 48 ± 14a
Female recipients N (%) 24 (24)b 17 (37)
Living donors N (%) 42 (42) 16 (35)
Repeat transplant N (%) 3 (3) 10 (22)c
Pre-emptive transplant N (%) 12 (12) 2 (4)
Time on dialysis (months) 28 (12–48) 48 (13–74)
HLA mismatch (IQR) 3 (2–4) 3 (2–4)
DGF N (%) 9 (9) 5 (11)
Hb at transplant g/L 127 ± 14 130 ± 15
Hb at 1 month g/L 115 ± 15 116 ± 16
No HLA-antibody N (%) 87 (86)d 33 (72)
Non-DSA N (%) 6 (6) 10 (22)a
DSA N (%) 8 (8) 3 (7)
No BPAR N (%) 65 (64) 35 (76)
Non-AMR N (%) 30 (30) 9 (20)d
AMR N (%) 6(6) 2 (4)
Time to AMR (months) 50 (40–60) 55 (49, 71)
Time to Non-AMR (months) 7 (1–19) 1 (0–8)
Results shown as mean ± SD, median and (IQR) or number (percentage).
a Signiﬁcantly different from No-RBCT (p b 0.05).
b Signiﬁcantly different from Post-RBCT and Pre + Post-RBCT (p b 0.05).
c Signiﬁcantly different from No-RBCT and Post-RBCT (p b 0.05).
d Signiﬁcantly different from all 3 other groups (p b 0.05).interaction terms, only the interaction between DSA and Post-RBCT (HR 7.2, 2.9–18.0,
p = 0.001) remained a signiﬁcant predictor of AMR.
Death-censored graft loss (Fig. 3 and Table 3) and combined patient and graft loss
(Table 3) was signiﬁcantly increased in the Pre + Post-RBCT group (HR 7.1 p b 0.001)
compared with all other transfusion groups. This difference persisted even after exclusion
of the 37 patients with preformed DSA (HR 4.9 95% CI 1.5–15.8 p = 0.007 and 3.9 1.7–7.8
p = 0.001 respectively). Neither gender nor retransplant were associated with graft or
patient loss. We used signiﬁcant univariate predictors of graft loss including DGF, HLA
antibody (DSA and Non-DSA), AMR and Non-AMR rejection and transfusion history in a
multivariate Cox Proportional Hazards model (Table 3). AMR, Non-AMR rejection and
Pre + Post RBCT were independently associated with death censored and all cause graft
loss. However DGF and DSA were no longer predictive by multivariate analysis.
4. Discussion
We show that the risk of AMR associatedwith the presence of DSA at
the time of transplant is modulated by exposure to RBCT. In our cohort,
AMR was predominantly observed only in sensitised patients with
DSA all of whom had received RBCT prior to transplant and were thenPost-RBCT
N = 48
Pre + Post-RBCT
N = 63
P value
51 ± 12a 47 ± 13 0.004
27 (56) 26 (41) 0.001
21 (44) 12 (19)c 0.014
0 (0) 14 (22)c 0.001
12 (25)d 1 (2)a b0.001
33 (13–70) 40 (17–79) 0.061
3 (3–4) 3 (2–4) 0.43
8 (17) 25 (40)d b0.001
116 ± 13 123 ± 13 b0.001
113 ± 16 109 ± 15 0.045
36 (75) 37 (59) Χ2 29.7 p = 0.001
6 (13) 6 (10)
6 (13) 20 (32) a
28 (58) 26 (41) a Χ2 21.0 p = 0.002
17 (35) 24 (38)
3(6) 13 (21)d
31 (2, 31, 60) 2 (0–30)
2 (0.5–15) 2 (1–7)
Fig. 1. Kaplan–Meier plot of time to AMR by transfusion status in all patients. Patients
with Pre + Post-RBCT had HR 4.1 (95%CI 1.6–10.8 p = 0.004) for AMR compared with
No-RBCT. Note Y-axis is truncated.
Fig. 2. a&b: Time to antibody mediated rejection (AMR) by antibody status at the time of
transplant in the combined 195 patients receiving No-RBCT, Pre-RBCT and Post-RBCT
(p = 0.56, panel a) and the 63 patients with Pre + Post-RBCT (p = 0.001, HR 13.9 DSA
vs No-antibody, panel b). Note different Y axis origin.
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and Pre + Post-RBCT were each independent predictors of AMR. How-
ever, there was a strong interaction between pre-transplant DSA and
Post-RBCT, which eliminated all other predictors (DGF, re-transplant,
gender), and conferred a 7.2 fold increase in the risk of AMR. In contrast,
patients with DSAwho received only Pre-RBCT or Post-RBCT, orwho re-
ceived no transfusion did not experience AMR.
Overall, patients with DSA had the highest rate of post-operative
transfusion. In our centres, the decision to give peri-operative transfu-
sion was solely determined by clinical need, authorised by different
clinical teams and, in all cases,madewithout knowledge of the patient's
anti-HLA antibody status. Our reported post-operative transfusion rate
of 43% is very similar to those reported elsewhere [28,29]. The reason
for the higher rate of peri-operative transfusion in patients with DSA
compared with Non-DSA is therefore uncertain. It may be due to the
greater medical and surgical complexities of this patient group and
their greaterwaiting timeon dialysis for example. However, it is notable
that there was no difference in gender, re-transplantation, deceased
donors or Pre-RBCT between the DSA and Non-DSA groups at time of
surgery, or between the haemoglobin at surgery or at 1 month post-
surgery. Although residual confounding by indication remains possible,
it is not possible to either entirely adjust or explain and this difference
requires further testing.
The immunological interaction of blood transfusion and transplanta-
tion is complex. Pre-RBCT is associated with better graft outcomes and
less acute rejection, and this is suggested to be due to immunomodulation
with down-regulation of an immune response and the induction of regu-
latory T-cells [11,30]. Indeed our study conﬁrms the continued beneﬁt of
Pre-RBCT alone with this group having the lowest rate of Non-AMR. We
also conﬁrm that Pre-RBCT is still associated with an increased risk of
HLA-antibody sensitisation. Several recent reports [28,29] raise some
concern that post-operative transfusion is associated with poor graft out-
come. However these studies did not consider sensitisation or prior trans-
fusion as potential modiﬁers and these factors may account for their
conﬂicting conclusions. Herewe report that peri-operative blood transfu-
sion is associated with an increased risk of AMR, but only in recipients
with pre-transplant DSA detected using solid phase assays, all of whom
had been previously exposed to RBCT and other sensitising events. Thiseffect of peri-operative transfusion was not found in recipients without
DSA, suggesting that the combination of DSA and peri-operative blood
transfusionmay be particularly detrimental to the transplanted graft. Im-
portantly, adverse events after peri-operative blood transfusion included
not only antibodymediated rejection, but also poorer long term graft out-
come and recipient death, independent of the risk of AMR and Non-AMR,
consistent with the ﬁndings of O'Brien et al. [28].
In light of our ﬁndings it is worth considering the immunological
mechanisms whereby blood transfusion could increase the pathogenic-
ity of pre-existing DSA. This might be through direct quantitative or
qualitative alterations in antibody or indirectly via speciﬁc transfusion
factors. Scornik et al. [16] have previously identiﬁed that re-exposure
to blood in those with prior sensitising events such as transplant or
pregnancy elicits a broad antibody response;ﬁndings that are consistent
Fig. 3. Time to death censored graft loss by transfusion status HR 7.1 (2.4–21.3) p b 0.001
for Pre + Post-RBCT compared with No-RBCT.
26 S. Fidler et al. / Transplant Immunology 29 (2013) 22–27with our study. Interestingly, broad recall of an antibody response to
previously exposed transplant antigens, rather than to the transfusion
antigens, was induced by third party transfusions. [31] Qian et al. [32]
have shown in a cardiac rodent model that pre-sensitisation with
allogeneic RBCT causes accelerated graft rejection in the presence of
complement and antibody binding to graft endothelium. Complement
activation products and quantitative changes in cytokines may be
present within stored blood products [33,34]. Norda and colleagues
found that stored plasma components may differ signiﬁcantly in
the amount and timing of complement activation products, particularly
C3a, which could speciﬁcally trigger pathological changes if pre-existing
effector DSA is present. Theoretically cytokines andother factors present
in blood products could also induce non-complement activating DSA
to class switch to IgG1 and/or IgG3 complement activating antibodies.
Mice models of transfusion related acute lung injury suggest that
MHC class I speciﬁc antibody binding to nonhematopoietic cells drives
complement activation and production of reactive oxygen species
[35]. T cell allorecognition of allogeneic HLA molecules, present even
in leucodepleted blood products, may be associated with speciﬁc
and non-speciﬁc immune activation including increased cytokine
production and cytotoxicity function. Whether exposure to RBCT in
sensitised patients stimulates an increase in the absolute amount or
breadth of DSA and/or class switching and complement bindingwas be-
yond the scope of this study. Serially monitoring these changes would
be informative however the frequency of sampling and interventions
for management of rejection which alter antibody measurement con-
found interpretation. These putative adverse effects of peri-operative
blood transfusion could be investigated further using in-vivo animal
models.
This data suggests that avoidance of peri-operative blood transfu-
sion or, given the impossibility of eliminating all transfusion risk,
establishing a newparadigm for RBCT in sensitised transplant recipients
should be considered. It is established that leucodepleted unmatched
RBCT does not reduce sensitisation [23] and therefore selecting HLA
matched blood with its signiﬁcantly reduced risk of HLA speciﬁc anti-
body production may be particularly suited to patients with DSA [36].
The use of HLAmatched blood transfusion products for renal transplan-
tation patients is feasible and may be effective within a clinical setting
[36,37]. Furthermore recipients with high levels of sensitization mayeven beneﬁt from pre-operative storage of autologous blood products
for use in the event of requiring a peri-operative blood transfusion
[38]. The beneﬁcial effects of blood transfusion on graft survival have
been reported to be associated with HLA-DR matching, and while HLA
typing of the blood donors was not available for this study it is highly
likely that the observed adverse effect is associated with speciﬁc HLA
mismatches between the blood donor and organ recipient [36].
In conclusion, we have shown that Pre-RBCT alone is still associated
with a lower rate of Non-AMR rejection and an increased risk of HLA an-
tibody.However, peri-operative blood transfusion in sensitised renal re-
cipients with DSA and prior transfusion is associated with AMR. Post-
RBCT may therefore be an additional factor modifying the risk of AMR
in patients with HLA-antibody. We also conﬁrm and expand upon the
previous ﬁndings that perioperative blood transfusion is associated
with poorer graft and patient survival, and show that this is most
evident in those with previous exposure to RBCT, independent of
acute rejection episodes. These ﬁndings suggest that RBCT remains a
potent and complex modiﬁable immunomodulator of renal transplant
outcomes and additional studies to further deﬁne mechanisms for
these effects are warranted.
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